-
- 2023
-
- DecGenBody Seoul Campus grand open
- FebUSA FDA approval of COVID-19 Ag Home Test
-
- 2022
-
- SepLaunch of Pangyo Bio Health Institute
- JulDonation of 20,000 COVID-19 Ag Home Test for vulnerable communities
- AprFirst Korea FDA approval of Influenza/COVID-19 Ag Triple
- FebAustralia TGA product quality certification of COVID-19 Ag kit
- FebKorea FDA approval of COVID-19 Ag Home Test
- FebEstablishment of GenBody SMART FACTORY with Samsung
-
- 2021
-
- NovFDA EUA approval of GenBody COVID-19 Ag RDT (Nasal swab)
- AugFDA EUA approval of GenBody COVID-19 Ag RDT (Throat swab)
- JulCompletion of R&D Center, G3 in Chungnam
- Feb(NIH) RADx program, 10million dollar research fund
-
- 2020
-
- DecKorea FDA approval of (FIA) GenBody FIA COVID-19 Ag
- JulKorea FDA approval of GenBody COVID-19 Ag RDT
- AprKorea FDA approval of GenBody DOA8 RDT (MET/THC, MOR/AMP, BZO/COC, KET/BAR)
- MarKorea FDA approval of GenBody COVID-19 IgM/IgG RDT
-
- 2019
-
- OctApproval to manufacture and sale of RDT products 23 parameters
- JunKorea FDA approval of (Biopsy test) Helicosign Dry
- MarKorea FDA approval of GenBody Influenza A/B Ag RDT
-
- 2018
-
- Mar
Completion of the second research center in Chungnam
- Fab
Completion of PT. GenBody Indonesia Sehat's the first research center (Bandung, Indonesia)
- Jan
Establishment of GenBody Japan Inc.(Tokyo,Japn)
- Mar
-
- 2017
-
- Dec
Launch arbovirus total diagnostic solution(MDx + RDT)
- Dec
Contract to export and supply Zika/ Dengue/ Chikungunya/ Yellow Fever rapid diagnostic test in Brasil (5.8 million tests)
- Nov
Establishment of PT. GenBody Indonesia Sehat Inc.(Bandung, Indonesia)
- Oct
Establishment of GenBody Inc. Suji branch(Suji, Gyeonggi-do)
- Aug
Completion of Cheonan HQ and first research center in Chungnam
- Aug
Launch of Arbovirus rapid diagnostic tests (12 parameters)
- Jan
Product quality certification for Chikungunya and Syphilis through Bahiafarma
- Dec
-
- 2016
-
- Oct
Contract to export and supply Zika diagnostic test (3.5 million tests) and quality certification for Chikungunya, Dengue IgG/IgM, NS1 Ag through Bahiafarma
- Jun
First in the world to be registered with the Brazilian government through Bahiafarma for Zika IgG/IgM rapid diagnostic test.
- May
Quality certification for Zika NS1 Ag rapid diagnostic test
- Mar
Development and evaluation of Chikungunya IgM diagnostic kits
- Mar
Launch of veterinary diagnostic tests for 36 parameters (The world’s largest quantities) and qGB analyzer (Hainan, China)
- Oct
-
- 2015
-
- Dec
First company to develop Zika RDT for humans in the world (Zka IgG/IgM RDT, Zika NS1 Ag RDT)
- Nov
First company to develop MERS-CoV RDT for humans in the world
- Nov
Second investment capital 500 million KRW
- Oct
Establishment of GenBody International Inc. in China
- Jul
Patent for exclusive use of mobile F-ICT (Korea USA)
- Feb
Exclusive License of diagnostic technology used Fullerene dye (Korea, USA, Japan, Germany)
- Dec
-
- 2014
-
- Dec
ISO13485 Certification
- Jun
Development of Cardiac Markers (TnI, CKMB, Myo, D-dimer)
- Apr
Development of markers for febrile disease (Leptospira, Tsutsugamushi, Hantanvirus)
- Apr
Approval of WHO Round 5 quality test for Malaria
- Dec
-
- 2013
-
- Jun
Development of Cancer markers (AFP, CEA, PSA, FOB)
- Mar
Patent for F-ICT ( Korea, USA, China )
- Mar
Patent for diagnosis method of fluorescence-based coumarin ( Korea, USA, China )
- Jun
-
- 2012
-
- Oct
Established GenBody Venture Startup in DanKook University
- Oct
